NS Pharma, Inc. – Trademark Portfolio
Entity Type: 03
NS Pharma, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 4 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include NS SUPPORT, DUCHENNE-OPEDIA, DUCHENNE DIARIES, and WE SPEAK DUCHENNE. The owner is based in Paramus, NJ.
140 East Ridgewood Avenue, Suite 280S
Paramus, NJ 07652
Showing of trademarks Trademarks
Trademark Classifications
NS Pharma, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does NS Pharma, Inc. have?
NS Pharma, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does NS Pharma, Inc. file in?
NS Pharma, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 41 (Education & Entertainment), Class 36 (Insurance & Financial). Class 35 covers advertising; business management; business administration; office functions.
What are NS Pharma, Inc.'s most well-known trademarks?
NS Pharma, Inc.'s registered trademark portfolio includes well-known marks such as NS SUPPORT, DUCHENNE-OPEDIA, DUCHENNE DIARIES, and WE SPEAK DUCHENNE. These are among 5 currently registered trademarks in the portfolio.
What is NS Pharma, Inc.'s trademark registration success rate?
NS Pharma, Inc. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.